BioRestorative's 1-for-20 Split Opens Today With About 1.4 Million Shares Outstanding

by Wesley Stroud · September 8, 2026

Micro-Cap Markets Correspondent, The MicroCap Herald

BioRestorative Therapies' 1-for-20 reverse stock split became effective at 4:30 p.m. Eastern time on Monday, Sept. 7, and its shares begin trading on a split-adjusted basis today, according to the company's Sept. 2 announcement. Because Sept. 7 was Labor Day and U.S. equity markets were closed, today's session is the first on the new basis. The shares trade on the Nasdaq Capital Market under BRTX.

The company gave a single stated reason. It said it "is effecting the Reverse Stock Split with the intention of regaining compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market."

The arithmetic leaves an unusually small share count for a listed issuer. BioRestorative had 27,622,556 shares outstanding as of Aug. 28, 2026; after the consolidation it expects approximately 1,381,128 shares outstanding. The new CUSIP is 090655705. Holders otherwise entitled to a fractional share will receive one whole share, rounded up.

The split also reverses a capital-structure change that shareholders approved only months ago. The announcement states that authorized common stock is being reduced from 1,500,000,000 shares to 75,000,000. BioRestorative's definitive proxy statement filed April 13, 2026 had asked shareholders to increase the authorized common share count from 75,000,000 to 1,500,000,000 — a twenty-fold increase. The 1-for-20 split now divides that figure by the same twenty, returning the authorized number to where it stood before the vote. The April proxy did not propose a reverse split.

The timing is tight against a hard date. The proxy disclosed that Nasdaq notified the company on March 26, 2026 that it did not meet the $1.00 minimum bid price requirement for continued listing, opening a compliance period of "180 calendar days from the date of the notice, or until September 22, 2026." To cure, the company must maintain "a minimum bid price of $1.00 or more for at least ten consecutive trading days."

Counting forward from today, Sept. 8 through Sept. 22 inclusive contains eleven trading days, with no U.S. market holidays in between. That leaves essentially no slack: a ten-session cure has to begin at or very near the opening of today's window to be completed inside the initial compliance period.

There is a further step available in principle. The proxy noted that "if we fail to meet such requirement within the initial 180 day period, Nasdaq may, under certain circumstances, grant a 180 day extension." The proxy offered no assurance that the company would remain listed even if it does regain compliance, and neither the proxy nor the split announcement says whether the company would seek one.

Behind the listing question is a balance sheet that depends on outside capital. For the three months ended March 31, 2026, BioRestorative reported cash and cash equivalents of $3,112,679 and marketable securities of $479,351, a net loss of $2,154,405, and $3,807,792 of net cash used in operating activities. The quarterly report includes going-concern language, stating that the conditions described "raise substantial doubt about the Company's ability to continue as a going concern for at least twelve months," and management said the company's "current funds will not be sufficient to enable the Company to fully complete its development activities or attain profitable operations."

The overhang is meaningful relative to the share count. The April proxy disclosed 24,994,143 shares issuable on exercise of outstanding options and warrants as of March 31, 2026, against 25,478,170 common shares outstanding as of April 6. Those are pre-split figures, and they show a derivative position roughly as large as the equity base itself.

The share count coming out of the split is worth dwelling on. Roughly 1.4 million shares outstanding is small even by micro-cap standards, and a share count that small tends to produce a modest public float, thin daily volume and wide quoted spreads. Consolidations lift the quoted price mechanically, but they do not add liquidity — they remove shares from the market, and price moves that would have been absorbed across a larger base land on a smaller one.

The plain risk note follows from all of the above. BRTX is a nano-cap stock with disclosed substantial doubt about its ability to continue as a going concern, a stated need for additional financing, a large options-and-warrants overhang and a Nasdaq bid-price deadline two weeks away. Reverse splits do not by themselves change a company's cash position, its burn rate or its need to raise money; they change the denominator. If financing follows, holders of a 1.4 million-share base would be diluted from a much smaller starting point than before.

What to watch over the next fortnight is narrow and specific: whether the closing bid price holds at or above $1.00 for ten consecutive trading days on or before Sept. 22, and whether the company discloses a financing or a request for a second compliance period.